HomeCompareRLGY vs JNJ

RLGY vs JNJ: Dividend Comparison 2026

RLGY yields 9.69% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JNJ wins by $8.9K in total portfolio value· pulled ahead in Year 7
10 years
RLGY
RLGY
● Live price
9.69%
Share price
$12.08
Annual div
$1.17
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.03
Full RLGY calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — RLGY vs JNJ

📍 JNJ pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRLGYJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RLGY + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RLGY pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RLGY
Annual income on $10K today (after 15% tax)
$823.26/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JNJ beats the other by $3,985.11/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RLGY + JNJ for your $10,000?

RLGY: 50%JNJ: 50%
100% JNJ50/50100% RLGY
Portfolio after 10yr
$25.8K
Annual income
$2,345.21/yr
Blended yield
9.08%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

RLGY
Analyst Ratings
11
Buy
8
Hold
2
Sell
Consensus: Buy
Altman Z
0.8
Piotroski
3/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RLGY buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRLGYJNJ
Forward yield9.69%2.13%
Annual dividend / share$1.17$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%28%
Portfolio after 10y$21.4K$30.3K
Annual income after 10y$1.03$4,689.40
Total dividends collected$996.00$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: RLGY vs JNJ ($10,000, DRIP)

YearRLGY PortfolioRLGY Income/yrJNJ PortfolioJNJ Income/yrGap
1$11,184$484.27$10,592$272.30+$592.00RLGY
2$12,220$253.09$11,289$357.73+$931.00RLGY
3$13,205$129.22$12,123$472.89+$1.1KRLGY
4$14,195$65.25$13,141$629.86+$1.1KRLGY
5$15,221$32.78$14,408$846.81+$813.00RLGY
6$16,303$16.42$16,021$1,151.60+$282.00RLGY
7← crossover$17,452$8.22$18,122$1,588.22$670.00JNJ
8$18,678$4.11$20,930$2,228.20$2.3KJNJ
9$19,987$2.06$24,792$3,191.91$4.8KJNJ
10$21,388$1.03$30,274$4,689.40$8.9KJNJ

RLGY vs JNJ: Complete Analysis 2026

RLGYStock

Realogy Holdings Corp., through its subsidiaries, provides residential real estate services. It operates through three segments: Realogy Franchise Group, and Realogy Brokerage Group. The Realogy Franchise Group segment franchises its residential real estate brokerages under the Century 21, Coldwell Banker, Coldwell Banker Commercial, Corcoran, ERA, Sotheby's International Realty, and Better Homes and Gardens Real Estate brand names. This segment also offers lead generation and relocation services. As of December 31, 2020, this segment's real estate franchise systems and proprietary brands had approximately 20,100 offices and 320,700 independent sales agents worldwide. The Realogy Brokerage Group segment owns and operates a full-service residential real estate brokerage business under the Coldwell Banker, Corcoran, and Sotheby's International Realty brand names to assist home buyers and sellers in the listing, marketing, selling, and finding homes. As of December 31, 2020, this segment owned and operated 670 brokerage offices with approximately 53,100 independent sales agents. The Realogy Title Group segment provides title, escrow, and settlement services to real estate companies, corporations, and financial institutions. This segment also serves as an underwriter of title insurance policies in connection with residential and commercial real estate transactions. Realogy Holdings Corp. was incorporated in 2006 and is headquartered in Madison, New Jersey.

Full RLGY Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this RLGY vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RLGY vs SCHDRLGY vs JEPIRLGY vs ORLGY vs KORLGY vs MAINRLGY vs ABBVRLGY vs MRKRLGY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.